Please login to the form below

Not currently logged in
Email:
Password:

Xolair

This page shows the latest Xolair news and features for those working in and with pharma, biotech and healthcare.

FDA clears Dupixent as first-ever drug for chronic rhinosinusitis with nasal polyps

FDA clears Dupixent as first-ever drug for chronic rhinosinusitis with nasal polyps

Roche and Novartis’ severe asthma therapy Xolair (omalizumab) has data showing it is effective as a treatment for polyps, but isn’t expected to be approved until the end of next

Latest news

More from news
Approximately 9 fully matching, plus 28 partially matching documents found.

Latest Intelligence

  • Pharma deals during August 2014 Pharma deals during August 2014

    This brings a much needed boost to its respiratory portfolio, which currently consists of Pulmozyme (cystic fibrosis) and Xolair (severe asthma) and products in clinical development, eg lebrikizumab (severe asthma).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health is an integrated communications agency designed for and inspired by the ever-changing face of healthcare. In London, we...

Latest intelligence

OPEN Health Graduates and the XP Support Group
During our graduate induction period in September 2018, we were asked to find a charity that could benefit from the expertise of the OPEN Health practices. We made the decision...
Alexander Devine Website has gone live!
As part of the OPEN Health CSR programme one of the charities we support is Alexander Devine. They are a local Children's Hospice based in Maidenhead who provide a truly...
Drug pricing and competition
Strengthening business competition and reducing anti-competitive practices
How the CMA is tackling high prices for essential drugs...

Infographics